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Summary
Insulin-like factor 3 (INSL3) is a peptide hormone produced in leydig cells of the testes. Its role 
in the adult male is unknown but INSL3 and its receptor RXFP2 have been linked to bone cell 
differentiation. It is speculated that low levels of INSL3 could be responsible for low bone min-
eral density in patients with primary osteoporosis and Klinefelter’s Syndrome.
The aim of this study was to assess plasma INSL3 in patients with osteoporosis and 
Klinefelter’s Syndrome compared to healthy males. 
Fourteen healthy males, 21 males with osteoporosis (4 primary and 17 secondary) and 4 
patients with Klinefelter’s Syndrome were studied. Plasma INSL3, testosterone, LH, FSH and 
Sex hormone-binding globulin were evaluated. 
Plasma INSL3 concentrations were similar in osteoporosis patients compared to healthy con-
trols (0.72 vs. 0.69 ng/mL, p=0.26). INSL3 was significantly higher in patients with primary 
osteoporosis (n=4) compared to age-matched healthy controls (n=8) (0.845 vs. 0.665 ng/mL, 
p=0.021). INSL3 levels in Klinefelter’s Syndrome patients were significantly lower compared to 
healthy controls (0.39 vs. 0.69 ng/mL, p=0.01). 
Plasma INSL3 levels were lower in Klinefelter’s Syndrome reflecting testicular failure. INSL3 
levels were not lower in men with osteoporosis. The relationship between INSL3, its receptor 
and bone metabolism requires further study. 
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Study 
Insulin-like factor 3 (INSL3) is a member of the relaxin peptide family and pro-
duced in the leydig cells of the testes in the adult male. INSL3 is understood to be 
involved in the first trans-abdominal phase of testicular descent in the male foe-
tus however little is known about the function of INSL3 in adult males (Ivell and 
Anand-Ivell, 2011). INSL3 binds to its receptor RXFP2 and the INSL3/RXFP2 signal-
ling pathway in the human osteoblast has been determined (Ferlin et al. 2011).
INSL3 concentrations remain constant throughout life, only declining in the age-
ing male (Anand-Ivell et al. 2006). They are also low in hypogonadal Klinefelter Syn-
drome (KS) (47 XXY) patients (Bay et al. 2005). It was therefore suggested that low 
INSL3 levels could contribute to low bone mineral density in some men with osteo-
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porosis or KS (Ivell and Anand-Ivell, 2011; Ferlin et al. 2008; Ferlin et al. (2010); Ferlin 
et al. (2011)). 
The aim of this study was to determine whether INSL3 levels were reduced in 
male patients with osteoporosis compared to healthy subjects and KS patients.
The following groups of subjects: 14 healthy adult men, 4 KS (47 XXY) patients, 
and 21 males with osteoporosis were studied. Consent was obtained and plasma 
samples were collected. This study was approved by the Norfolk Research Ethics 
Committee. 
INSL3 was measured using a commercial enzyme immunoassay kit (Phoe-
nix Pharmaceuticals, Inc. Burlingame, CA). Testosterone, LH, FSH and sex-hor-
mone-binding globulin (SHBG) were measured using the Cobas e ® (Roche Diagnos-
tics) by Electrochemiluminescence immunoassay. 
Comparison for baseline characteristics including age, testosterone (total and 
free), LH, FSH, SHBG and INSL3 were tested for statistical significance using the 
Mann-Whitney U test for non-parametric data. Significance was defined as P<0.05. 
Our results show that there was no significant difference (p=0.2662) in INSL3 lev-
els between healthy controls and osteoporosis patients [Healthy controls n=14, 0.69 
(0.175) ng/mL, osteoporosis patients n=21, 0.72 (0.3) ng/mL and KS patients n=4, 
0.39 (0.11) ng/mL; INSL3 plasma levels are shown as median values with interquar-
tile range in bracket]. Plasma INSL3 levels were significantly lower in KS patients 
compared to healthy controls (p=0.0066) and osteoporosis patients (p=0.0054).
In the osteoporosis group, 4 patients had primary osteoporosis and the remain-
ing 17 had secondary osteoporosis. Eight healthy controls were subsequently age-
matched to the primary osteoporosis group. INSL3 levels were significantly higher in 
patients with primary osteoporosis compared to the age-matched healthy controls (p 
Figure 1. INSL3 concentrations (ng/mL) in age-matched healthy controls, primary and secondary osteopo-
rosis patients and KS patients. The box plots display the median (middle line), the interquartile range (25th 
percentile and 75th percentile, represented by the box). The bottom whisker represents the 2.5th percentile 
and the top whisker represents the 97.5th percentile. * = p<0.05.
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= 0.0214): [Healthy controls aged-matched to primary osteoporosis n=8, 0.665 (0.128) 
ng/mL, primary osteoporosis n=4, 0.845 (0.205) ng/mL, secondary osteoporosis n=17, 
0.68 (0.33) ng/mL; INSL3 plasma levels are shown as median values with interquar-
tile range in bracket]. Biochemical characteristics including testosterone (free and 
total), FSH, LH and SHBG were not significantly different between groups.
A significant difference in INSL3 was seen between primary osteoporosis (n=4) 
and KS patients (n=4) (p=0.0294). No significant difference in INSL3 was seen 
between the primary and secondary osteoporosis patients (p= 0.1684), or between 
healthy controls (n=8) and secondary osteoporosis patients (p=0.3818) (Figure 1).
Currently there are no published studies on circulating INSL3 in male patients 
with osteoporosis. 
Our results show that plasma INSL3 levels are significantly higher between 
patients with primary osteoporosis compared to age-matched healthy subjects. Other 
biochemical characteristics were not statistically significant between the groups. This 
suggests that there may be a unique defect present in males with primary osteopo-
rosis resulting in these high circulating INSL3 levels. Alternatively, the role of INSL3 
in bone physiology may be more complex than first thought. This preliminary study 
was limited by the small number of participants. 
In conclusion, our data does not support the hypothesis that low INSL3 levels are 
present in males with osteoporosis. Our data further confirms previous studies show-
ing low INSL3 levels in KS patients. Further work is required in order to validate 
these findings. 
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